GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » Capex-to-Operating-Income

IXICO (LSE:IXI) Capex-to-Operating-Income : 0.00 (As of Sep. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IXICO Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

IXICO's Capital Expenditure for the six months ended in Sep. 2023 was £-1.05 Mil. Its Operating Income for the six months ended in Sep. 2023 was £-0.52 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


IXICO Capex-to-Operating-Income Historical Data

The historical data trend for IXICO's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO Capex-to-Operating-Income Chart

IXICO Annual Data
Trend Sep13 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.32 1.36 1.97 2.47 -

IXICO Semi-Annual Data
Sep13 Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.73 6.33 1.59 - -

Competitive Comparison of IXICO's Capex-to-Operating-Income

For the Biotechnology subindustry, IXICO's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IXICO's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where IXICO's Capex-to-Operating-Income falls into.



IXICO Capex-to-Operating-Income Calculation

IXICO's Capex-to-Operating-Income for the fiscal year that ended in Sep. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.963) / -1.437
=N/A

IXICO's Capex-to-Operating-Income for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.046) / -0.524
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IXICO  (LSE:IXI) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


IXICO Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of IXICO's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


IXICO (LSE:IXI) Business Description

Industry
Traded in Other Exchanges
Address
15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN
IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines